Baricitinib (Olumiant) accepted for restricted use within NHS Scotland for treatment of moderate to severe atopic dermatitis

Treatment is restricted to adult patients who are candidates for systemic therapy and who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.

Source:

Scottish Medicines Consortium